Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Novelion (NVLN.TO)

Novelion (NVLN.TO)

0.00
-0.00 (0.00%)
52 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Novelion(NVLN.TO)

Jan 17, 2005
Closed their merger in December, so hopefully the share price indigestion that comes with mergers is over. Fundamentally not expensive, Chart is interesting. Balance sheet is in good shape. His holdings is on a paired/trade situation with a short on Eyetech (EYET-Q). Very beaten up stock, but has some decent prospects.
Photo of Andrew McCreathAndrew McCreath
Owned
Unlock Rating
$20.05

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Jan 07, 2005
Strong balance sheet. Outlook for the sale of their product is quite encouraging.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$20.98

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Dec 23, 2004
Has had a disappointing year. Some competitive drugs have been approved by the FDA which will attack part of its market share. Growth profile for the next couple of years is not that strong.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$18.59

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Dec 17, 2004
Recently made an intelligent acquisition that diversified the product base. Market didn't see it that way, but over time, it should strengthen the price of QLT.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$19.00

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Dec 01, 2004
Dropped below the 200 day moving average.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$19.01

Stock price when the opinion was issued

biotechnologypharmaceutical
TRADE

Novelion(NVLN.TO)

Nov 25, 2004
Facing some competition which is worrisome. In the smaller end of the ocular market and would prefer companies in the other end.
Photo of Michael SmedleyMichael SmedleyUnlock Rating
$18.22

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Nov 11, 2004
Not too bullish on the stock, but wouldn't necessarily sell it if you own. Their key drug Visudine is facing some competition. Upside could be limited in the short term.
Photo of John ZechnerJohn ZechnerUnlock Rating
$19.30

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Novelion(NVLN.TO)

Nov 09, 2004
Their Visudine product is a leader with the highest market share in the last few months. Their prostate cancer product will be significant. Attractive valuation. Has cash.
Photo of Danny TomkaDanny Tomka
Owned
Unlock Rating
$19.18

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Nov 08, 2004
Has not been a big winner over the last year, but thinks it's going to do pretty well. Likes its product.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$19.08

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Oct 20, 2004
Has a great product for dealing with macular degeneration but has had some very disappointing clinical results. Increasing competition in their product. Too expensive.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$19.57

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Novelion(NVLN.TO)

Sep 17, 2004
Competition has a product that has more application for macular degeneration. A little bit of a gamble, but is certainly a popular application.
Photo of Ross HealyRoss HealyUnlock Rating
$20.55

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Sep 16, 2004
Not a contrarian stock. Still in the sexy kind of biotech miracle cure stage. Got way ahead of itself. Have a lot of egss in one basket which makes them vulnerable. A lot of competition. Needs to be cheaper and more product diversification.
Photo of Ben StadelmannBen Stadelmann
No
Unlock Rating
$20.55

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Sep 14, 2004
Vrey volatile. In the health care sector, would look more to the US, such as Johnson & Johnson.
Photo of Ian NakamotoIan Nakamoto
No
Unlock Rating
$20.69

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Sep 08, 2004
Revenues and earnings are doing pretty well. Trades at about 18 X earnings. A lot of cash. Involved in a questionable acquisition in the US. Some competition. We'll continue to stall in the foreseeable future.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$19.16

Stock price when the opinion was issued

biotechnologypharmaceutical
TRADE

Novelion(NVLN.TO)

Aug 26, 2004
More competitions coming in. It is a great business. At this level, the stock is reasonably attractive. However, up and downs for this stock is limited.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
No
Unlock Rating
$21.36

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 16 to 30 of 190 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video